公开(公告)号：US20210069295A1

公开(公告)日：2021-03-11

申请号：US16977318

申请日：2018-11-09

Applicant: STC. UNM

Inventor： Vojo P. Deretic ,  Jingyue Jia

IPC: A61K38/17 ,  A61K31/4706 ,  A61K38/05 ,  A61K31/133 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/7016 ,  C07K16/28 ,  A61K31/732 ,  A61K31/4745 ,  A61K31/52 ,  A61K31/436 ,  A61K31/675 ,  A61K31/437 ,  A61K31/353 ,  A61K31/522 ,  A61K31/12 ,  A61K31/05

Abstract: The present invention is directed to the discovery that Galectins and in particular, Galectin-8 and Galectin-9 control mTor response (Galectin-8 is a mTOR inhibitor and Galectin-9 is modulator/upregulator of AMPKinase) to endomembrane damage and these compositions can be used, either alone or together, optionally in combination with a lysomotropic agent and other bioactive agents as compositions for the treatment of autophagy-elated diseases. The present invention is directed to pharmaceutical compositions and methods for treating autophagy-related diseases as described herein.

公开(公告)号：US20200262916A1

公开(公告)日：2020-08-20

申请号：US16791520

申请日：2020-02-14

Applicant: STC. UNM

Inventor： Vojo P. Deretic ,  Yuexi Gu ,  Graham Timmins

IPC: C07K16/28 ,  A61K31/4439 ,  A61K31/5025 ,  A61K31/502 ,  A61K31/53

Abstract: The present invention is directed to the elucidation of the mechanism that human Atg8 protein regulates endolysosomal systems in the cell and the role this protein plays in mediating autophagy. Methods of treating autophagy-mediated disease states with agonists/antagonists of Atg8, STX16 and STX17 proteins are disclosed as are pharmaceutical compositions.